BridgeBio

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. 

BridgeBio is seeking partners for the following programs:

• BBP-589 – Recombinant collagen 7 for dystrophic epidermolysis bullosa (rDEB)
  • Completed Phase 2 clinical trial designed to evaluate safety and tolerability of BBP-589, as well as clinical proof-of-concept, and initiated a Phase 2 extension study
• BBP-681 – Topical PI3KA inhibitor for venous and lymphatic malformations (VM and LM)
  • Phase 1/2 clinical trial underway
• BBP-711 – GO inhibitor for primary hyperoxaluria type 1 (PH1) and recurrent kidney stone formers
  • Phase 1 clinical trial completed
• BBP-561 – KLK 5/7 inhibitor for Netherton syndrome
  • Investigational New Drug (IND) enabling studies underway
• BBP-818 – Adeno-associated virus (AAV) gene therapy for classic galactosemia
  • IND-enabling studies underway
• BBP-815 – AAV gene therapy for nonsyndromic hearing loss 
  • Preclinical development
• BBP-472 – PI3KB inhibitor for PTEN autism
  • Preclinical development